Bravecto

Verify with FDA CVM →

216 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
216
Total Reports
21
Deaths Reported
970.0%
Death Rate

Active Ingredients

Bravecto

Administration Routes

UnknownOralTopicalSubcutaneous

Species Affected

Dog 192
Cat 24

Most Affected Breeds

Retriever - Labrador 27
Domestic Shorthair 17
Retriever - Golden 16
Crossbred Canine/dog 12
Terrier - Bull - American Pit 12
Boxer (German Boxer) 9
Bulldog - French 9
Shepherd Dog - German 8
Terrier (unspecified) 6
Shepherd Dog - Australian 5

Most Reported Reactions

Vomiting 27
Seizure NOS 24
Lack of efficacy - NOS 23
Diarrhoea 15
Ataxia 15
Not eating 12
Elevated serum alkaline phosphatase (ALP) 12
Intentional misuse 12
Lethargy (see also Central nervous system depression in Neurological) 11
Death 10
Lethargy (see also Central nervous system depression in 'Neurological') 10
Death by euthanasia 10

Outcome Breakdown

Ongoing
141 (65.3%)
Recovered/Normal
33 (15.3%)
Outcome Unknown
21 (9.7%)
Died
11 (5.1%)
Euthanized
10 (4.6%)

Data Summary

Metric Value
Total adverse event reports 216
Reports involving death 21
Case-fatality rate (reported events) 970.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Bravecto Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 216 adverse event reports referencing Bravecto, including 21 reports in which the animal died — a 970.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Bravecto. Reported administration routes include Unknown, Oral, Topical, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Bravecto reports are Dog (192 reports), Cat (24 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (27), Domestic Shorthair (17), Retriever - Golden (16) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Bravecto are Vomiting (27), Seizure NOS (24), Lack of efficacy - NOS (23), Diarrhoea (15). Of the 216 reports with a coded outcome, Ongoing is the leading category at 65.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Bravecto.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial